Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5

CYP3A5 Polymorphism affects the increase in CYP3A activity after living Kidney transplantation in patients with end stage renal disease

(2015) Y. Suzuki et al.   CLINICAL THERAPEUTICS

A proposal for scientific framework enabling specific population drug dosing recommendations

(2015) Pravin R. Jadhav et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Application of a Physiologically Based Pharmacokinetic Model Informed by a Top-Down Approach for the Prediction of Pharmacokinetics in Chronic Kidney Disease Patients

(2014) Hiroyuki Sayama et al.   AAPS Journal

Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization

(2014) J. Hicks et al.   CURRENT DRUG METABOLISM

Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins

(2014) Kyra J. Barnes et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Albumin–drug interaction and its clinical implication

(2013) Keishi Yamasaki et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Pharmacokinetics of Intravenous Conivaptan in Subjects With Hepatic or Renal Impairment

(2013) Michael J. Roy et al.   CLINICAL PHARMACOKINETICS

Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport

(2013) Catherine K. Yeung et al.   KIDNEY INTERNATIONAL

Possibility of Decrease in CYP1A2 Function in Patients With End-Stage Renal Disease

(2013) Masayuki Tsujimoto et al.   THERAPEUTIC APHERESIS AND DIALYSIS

Effects of Decreased Vitamin D and Accumulated Uremic Toxin on Human CYP3A4 Activity in Patients with End-Stage Renal Disease

(2013) Masayuki Tsujimoto et al.   Toxins

Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation

(2012) Ping Zhao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Regulatory Perspectives on Designing Pharmacokinetic Studies and Optimizing Labeling Recommendations for Patients With Chronic Kidney Disease

(2012) Lei Zhang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Severe Renal Impairment

(2011) Kathleen Butler et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Modeling and predicting drug pharmacokinetics in patients with renal impairment

(2011) Karen Rowland Yeo et al.   Expert Review of Clinical Pharmacology

Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist

(2010) John W. Bauman et al.   INVESTIGATIONAL NEW DRUGS

Drug Development Perspective on Pharmacokinetic Studies of New Drugs in Patients With Renal Impairment

(2009) R L Lalonde et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Public Health Consequences of Chronic Kidney Disease

(2009) D E Weiner   CLINICAL PHARMACOLOGY & THERAPEUTICS

ESRD Impairs Nonrenal Clearance of Fexofenadine but not Midazolam

(2009) T. D. Nolin et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport

(2008) TD Nolin et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications

(2008) Y Zhang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Is This the Drug or Dose for You?: Impact and Consideration of Ethnic Factors in Global Drug Development, Regulatory Review, and Clinical Practice

(2008) S-M Huang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS